Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Assiya Maikenova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity

    by Assiya Maikenova, Assel Urazbayeva, Zhuldyz Myrzabay, Nazym Askambayeva, Alexander Gulyayev, Alexander Digai, Ainur Tauekelova, Ayaulym Nurgaziyeva, Zhanel Mukhanbetzhanova, Mohamad Aljofan

    Chemotherapy-induced cardiotoxicity is a serious consequence of chemotherapy during cancer treatment that can affect any patient. The purpose of this review is to highlight the development of cardiotoxicity associated with the use of anthracyclines or trastuzumab and to examine prevention and treatment methods using polyphenols, biologically active substances that hold significant therapeutic potential. The main mechanisms of this pathology, modern biomarkers for detection, and the classification and biological activity of polyphenols are discussed. Emphasis is placed on polyphenols found in grapes and their antioxidant potential as a protector of the cardiovascular system.


  • Open Access

    Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy

    by Shynggys Sergazy, Kulzhan Berikkhanova, Alexandr Gulyayev, Zarina Shulgau, Assiya Maikenova, Ruslan Bilal, Milan Terzic, Zhaxybay Zhumadilov, Mohamad Aljofan

    Significant progress has been made in developing cell-based drug delivery systems that utilize the intrinsic biological properties of various cell types—erythrocytes, leukocytes, platelets, stem cells, and even spermatozoa—to improve drug targeting, bioavailability, and biocompatibility. This review presents an integrative analysis of the latest advances in cell-based drug delivery systems, focusing on their design, pharmacokinetics, cellular interactions, and therapeutic potential. We specifically focus on hybrid microrobots and membrane-coated nanocarriers as emerging biohybrid platforms. Despite these advances, translation to the clinical phase remains constrained by persistent limitations, such as immune clearance, loss of membrane integrity during cargo loading, limited tissue penetration of carrier cells, and manufacturing challenges. Finally, we highlight future directions, including CAR-cell combinations and artificial cell engineering, that promise to expand the clinical utility of cell-based drug delivery systems in oncology, infectious diseases, and regenerative medicine.


  • Open Access

    Harnessing Mammalian- and Plant-Derived Exosomes for Drug Delivery: A Comparative Review

    by Shynggys Sergazy, Sergazy Adekenov, Ilya Khabarov, Kymbat Adekenova, Assiya Maikenova, Mohamad Aljofan

    Exosomes, nanoscale vesicles involved in intercellular communication, have garnered significant attention for their potential in drug delivery and therapeutic applications. This review provides a comparative analysis of mammalian-derived exosomes, particularly milk-derived exosomes, and plant-derived exosome-like nanoparticles (PDENs). It explores their biogenesis, bioactivities, and functional similarities, including their roles in cellular communication, immune modulation, and disease therapy. While milk-derived exosomes exhibit promising biocompatibility and stability for targeted delivery, PDENs offer distinct advantages, such as scalability and inherent bioactivities, derived from their plant sources. Despite similarities in their structure and cargo, PDENs differ in lipid composition and protein profiles, reflecting plant-specific functions. Emerging research highlights the therapeutic potential of PDENs in managing inflammation, oxidative stress, and other diseases, emphasizing their utility as functional food components and nanocarriers. However, challenges related to their chemical stability and large-scale production require further investigation. This review underscores the need for advanced studies to fully harness the potential of these natural nanocarriers in drug-delivery systems and therapeutic interventions.